Pfizer hopes not to get stung
New clinical trial entrants include the group’s attempt at targeting Sting, a field that has seen many setbacks.
Warning signs for Xencor
Data on the group’s lead project, the PD-1 x CTLA-4 bispecific vudalimab, are far from emphatic.
Janux gives conditionally acting therapeutics hope
Early activity of JANX007 in prostate cancer sees Janux stock gain 190%.
Pfizer shuffles its deck post-Seagen
The group’s B7-H4-targeting bispecific is out, in favour of Seagen’s ADC.
